Syncona
Limited
Autolus announces
confidential submission for potential IPO
6 March 2018
Syncona Ltd, a leading healthcare company focused on investing
in and building global leaders in life science, today notes the
announcement from its portfolio company, Autolus, that it has made
a confidential submission of a draft registration statement on Form
F-1 to the U.S. Securities and Exchange Commission relating to a
potential initial public offering of ordinary shares in
the United States.
The process is at a preliminary stage and an initial public
offering may or may not be pursued by Autolus. Syncona is the
largest shareholder in Autolus and is highly supportive of the
company over the long term in line with Syncona’s strategy to build
global leaders in life science and deliver transformational
treatments to patients.
This announcement is being made pursuant to and in accordance
with Rule 135 under the U.S. Securities Act of 1933, as amended,
and does not constitute an offer to sell or the solicitation of an
offer to buy securities, and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of that jurisdiction.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver
Tel: +44 (0) 20 7611 2031
+44 (0) 7921 822 994
Tulchan Communications
Martin Robinson
Lisa Jarrett-Kerr
Tel: +44 (0) 207 353 4200
Copies of this press release and other corporate information
can be found on the company website at: www.synconaltd.com
Forward-looking statements – this
announcement contains certain forward-looking statements with
respect to the portfolio of investments of Syncona Ltd. These
statements and forecasts involve risk and uncertainty because they
relate to events and depend upon circumstances that may or may not
occur in the future. There are a number of factors that could cause
actual results or developments to differ materially from those
expressed or implied by these forward-looking statements and
forecasts. Nothing in this announcement should be construed as a
profit forecast.
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on
investing in and building global leaders in life science. Our
vision is to deliver transformational treatments to patients in
truly innovative areas of healthcare while generating superior
returns for shareholders. Our current investment portfolio consists
of seven high quality companies in life science and a leading range
of fund investments.
We seek to partner with the best, brightest and most ambitious
minds in science to build globally competitive businesses. We are
established leaders in gene therapy, cell therapy and advanced
diagnostics, and focus on delivering dramatic efficacy for patients
in areas of high unmet need.
Our market leading funds portfolio seeks to generate superior
returns by investing in long only and alternative investment funds.
This represents a productively deployed evergreen funding base
which enables us to take a long term approach to investing in life
sciences as we target the best new opportunities and support our
existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in
UK science, the Wellcome Trust, original founder of Syncona, and
Cancer Research UK, both of which are significant shareholders in
our business. We make a donation of 0.3% of Net Asset Value
to a range of charities each year.